CBD Life Sciences CBDL through its wholly owned subsidiary, LBC Bioscience Inc. is introducing a product that is infused with both Delta-8 & Delta-9.
The Green Apple flavored product the company is introducing are Infused Gummies with 15mg of Delta-8 & 10mg of Delta-9 per gummy and will come in a 15-count jar. According to the company this product is ideal for easing the mind while staying focused. All products are carefully blended to ensure consistency along with third party lab testing for verification. This product will be available in store as of August 18, with the LBC website to follow within the next couple of days.
President & CEO Lisa Nelson stated, "We have been working diligently to experiment and create a new product to deliver to our consumers & beloved shareholders and we will continue to keep the public updated moving forward!"
About LBC Bioscience
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesale a full line of cannabidiol based organic products. The company's offerings include 100mg CBD Bath Bombs in a variety of scents, Delta 8 Gummies, 1500mg Premium Berry Drops, CBD Pain Cream, CBD Oils and CBD Pet Treats.and a variety of skincare products.
Photo: Courtesy of CBD Life Sciences
Related News
CBD Life Sciences Debuts New Delta-9 Gummies With 400Mg of CBD
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.